Evidence Review
PCOS and Reproductive Outcomes
The most comprehensive recent evidence comes from a 2024 systematic review and meta-analysis by Fitz et al. (PMID 38163998), which analyzed 30 trials involving 2,230 participants to inform updated international PCOS guidelines. The review found benefits for metabolic measures — particularly fasting insulin and HOMA-IR — and suggested possible improvements in ovulation rates, though the authors noted variability in trial quality limited strong conclusions.
An earlier meta-analysis by Unfer et al. (PMID 29042448, Endocrine Connections, 2017) examined 9 randomized controlled trials (247 cases, 249 controls). Myo-inositol significantly reduced fasting insulin and improved HOMA-IR; SHBG (sex hormone binding globulin, a marker of androgen excess) increased significantly after 24+ weeks. This is clinically relevant because elevated androgens in PCOS drive many of its most burdensome symptoms.
Costantino et al. (PMID 19499845) conducted a double-blind trial in 42 women with PCOS comparing myo-inositol to placebo. Triglycerides dropped dramatically — from a mean of 195 mg/dL to 95 mg/dL — in the inositol group. Ovulation was restored in 16 of 23 women in the treatment arm, compared to just 4 of 19 in the placebo group. These are striking numbers for a non-pharmaceutical intervention.
Fertility and Egg Quality
Ciotta et al. (PMID 21744744) ran a double-blind trial examining oocyte quality in PCOS patients undergoing IVF. Women received either 2 g myo-inositol + 200 mcg folic acid daily or folic acid alone for three months before egg retrieval. The inositol group showed significantly improved follicle development, higher oocyte recovery rates, and better embryo quality scores. This matters not just for IVF patients — it reflects broader improvements in ovarian function that could support natural conception.
Glucose and Metabolic Health
Miñambres et al. (PMID 29980312, Clinical Nutrition, 2019) conducted the most statistically rigorous meta-analysis on inositol and glucose, pooling 20 RCTs with 1,239 subjects across diverse populations (PCOS, metabolic syndrome, gestational diabetes risk). Inositol significantly reduced fasting plasma glucose and insulin resistance markers. Importantly, there was no significant effect on HbA1c or BMI, suggesting the mechanism is direct insulin sensitization rather than metabolic weight changes. This is a meaningful distinction for people who are already lean but insulin resistant.
Croze and Soulage (PMID 23764390, Biochimie, 2013) provide the most thorough mechanistic review. They describe how inositol phosphoglycans (IPGs) function as insulin second messengers — essentially relay switches that amplify the insulin signal inside cells. A deficiency in IPG availability, or genetic impairments in inositol metabolism, can cause insulin signaling to "short circuit" even when insulin levels are normal. This explains why some people with insulin resistance have normal fasting insulin but poor cellular glucose uptake.
Anxiety and Panic Disorder
The psychiatric application of inositol remains one of the more surprising areas of research. Benjamin et al. (PMID 7793450, American Journal of Psychiatry, 1995) ran a double-blind crossover trial in 21 patients with panic disorder. Participants took 12 g/day inositol or placebo for four weeks each. Inositol reduced panic attack frequency significantly more than placebo, with improvements also seen in agoraphobia ratings. Adverse effects were minimal.
Palatnik et al. (PMID 11386498, Journal of Clinical Psychopharmacology, 2001) pushed further with a head-to-head comparison against fluvoxamine (an SSRI used for panic). In a crossover design with 20 patients, inositol reduced panic attacks by 4.0 per week versus 2.4 per week for fluvoxamine. Hamilton Anxiety Scale scores improved comparably between the groups, but inositol caused significantly fewer gastrointestinal side effects. This does not mean inositol replaces SSRIs — sample sizes are small and the follow-up periods are short — but it does support inositol as a meaningful intervention for panic with a favorable tolerability profile.
Evidence Summary
The evidence for myo-inositol is strongest in PCOS (multiple meta-analyses, moderate-to-strong evidence), metabolic insulin resistance (meta-analysis of 20 RCTs), and fertility support (solid double-blind trial data). The anxiety/panic research is promising but comes from small trials conducted primarily in the 1990s and early 2000s — it warrants more large-scale replication. Inositol's excellent safety profile at standard doses (2–4 g/day) makes it a reasonable option to discuss with a healthcare provider for the conditions above.